Relapse prevention in schizophrenia: A systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics

Molecular Psychiatry

Volumn 18, Issue 1, 2013, Pages 53-66

  Kishimoto, T ^a   Agarwal, V ^b   Kishi, T ^a   Leucht, S ^c   Kane, J M ^a,d,e,f   Correll, C U ^a,d,e,f  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

antipsychotics; long term treatment; maintenance; meta analysis; relapse prevention; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ARTICLE; CLINICAL TRIAL; DRUG TOLERABILITY; HOSPITALIZATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; FOLLOW-UP STUDIES; HUMANS; RECURRENCE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84871288077     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.143     Document Type: Article

References (50)

1. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. J Clin Psychiatry 1996; 57(Suppl 11): 68-71.
2. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Safety 2011; 20: 177-184.
3. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W et al. Second-generation antipsychotic drugs and extrapyramidal side effects: A systematic review and metaanalysis of head-to-head comparisons. Schizophr Bull. Advance online publication, 31 May 2010 (e-pub ahead of print).
4. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-425.
5. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65: 267-272.
6. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-1773.
7. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomized controlled trial. JAMA 2003; 290: 2693-2702.
8. Lieberman JA, Stroup TS, Mcevoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
9. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087.
10. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomized clinical trial. Lancet 2008; 371: 1085-1097.
11. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222.
12. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley Jr. CM. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998; 172: 499-505.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
15. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161(2 Suppl): 1-56.
16. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
17. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55(Suppl B): 102-106.
18. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 32: 683-697.
19. Speller JC, Barnes TR, Curson DA, Pantelis C, Alberts JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry 1997; 171: 564-568.
20. Daniel DG, Wozniak P, Mack RJ, McCarthy BG. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 1998; 34: 61-69.
21. Rosenheck R, Evans D, Herz L, Cramer J, Xu W, Thomas J et al. How long to wait for a response to clozapine: A comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr Bull 1999; 25: 709-719.
22. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000; 15: 13-22.
23. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22.
24. de Sena EP, Santos-Jesus R, Miranda-Scippa A, Quarantini LC, Oliveira IR. Relapse in patients with schizophrenia: A comparison between risperidone and haloperidol. Rev Bras Psiquiatr 2003; 25: 220-223.
25. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M et al. Efficacy and safety of aripiprazole vs haloperidol for longterm maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6: 325-337.
26. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L et al. Atypical and conventional antipsychotic drugs in treatment-naïve first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003.
27. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003; 160: 1405-1412.
28. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L et al. Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry 2005; 162: 947-953.
29. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396-1404.
30. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS et al. Olanzapine and haloperidol in first episode psychosis: twoyear data. Schizophr Res 2006; 86: 234-243.
31. Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2007; 68: 1763-1774.
32. Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Longterm efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008; 28(2 Suppl 1): S29-S35.
33. Crespo-Facorro B, Perez-Iglesias R, Mata I, Caseiro O, Martinez- Garcia O, Pardo G et al. Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. J Psychiatr Res 2010; 45: 763-769.
34. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158: 1835-1842.
35. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163: 2080-2089.
36. Rosenheck RA, Leslie DL, Doshi JA. Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making. Psychiatr Serv 2008; 59: 515-520.
37. Rosenheck RA. Pharmacotherapy of first-episode schizophrenia. Lancet 2008; 371: 1048-1049.
38. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009; 373: 31-41.
39. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010; 71: 1115-1124.
40. Leucht S, Heres S, Kissling W, Davis JM. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 2011; 14: 269-284.
41. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103-108.
42. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R et al. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70(Suppl 4): 1-46.
43. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127: 83-92.
44. Lambert M, Schimmelmann BG, Schacht A, Suarez D, Haro JM, Novick D et al. Differential 3-year effects of first- versus secondgeneration antipsychotics on subjective well-being in schizophrenia using marginal structural models. J Clin Psychopharmacol 2011; 31: 226-230.
45. Rosenheck RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry 2007; 191: 238-245.
46. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010; 35: 1997-2004.
47. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res 2010; 123: 225-233.
48. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011; 17: 97-107.
49. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol; Advance online publication, 18 October 2011; doi:10.1038/nrendo. 2011.156 (e-pub ahead of print).
50. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet 2003; 361: 1581-1589.